Alefacept
Amevive (alefacept) is a protein pharmaceutical. Alefacept was first approved as Amevive on 2003-01-30. It is used to treat psoriasis in the USA. The pharmaceutical is active against T-cell surface antigen CD2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Alefacept
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Amevive | alefacept | Astellas Pharma | N-125036 DISCN | 2003-01-30 | 2 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| psoriasis | EFO_0000676 | D011565 | L40 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0215 | Injection, alefacept, 0.5 mg |
Clinical
Clinical Trials
39 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 4 | 4 | 6 | 6 | 20 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 1 | — | 1 | — | 2 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | 1 | — | 1 | — | 2 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 1 | — | 1 | — | 2 |
| Pityriasis rubra pilaris | D010916 | — | L44.0 | — | — | — | 1 | — | 1 |
| Exfoliative dermatitis | D003873 | — | L26 | — | — | — | 1 | — | 1 |
| Pityriasis | D010915 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | — | D89.81 | 1 | 2 | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney transplantation | D016030 | — | — | 1 | 2 | — | — | 1 | 4 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | 1 | — | — | — | 1 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | — | 1 | — | — | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
| Bronchiolitis obliterans syndrome | D000092122 | — | — | — | 1 | — | — | — | 1 |
| Lichen planus | D008010 | — | L43 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | HP_0001903 | D64.9 | 1 | — | — | — | 1 | 2 |
| Aplastic anemia | D000741 | HP_0001915 | D61.9 | 1 | — | — | — | 1 | 2 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
| T-cell lymphoma | D016399 | — | — | 1 | — | — | — | — | 1 |
| T-cell lymphoma peripheral | D016411 | — | — | 1 | — | — | — | — | 1 |
| T-cell lymphoma cutaneous | D016410 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | — | — | — | 1 | 1 |
| Alopecia | D000505 | HP_0002293 | L64 | — | — | — | — | 1 | 1 |
| Neutropenia | D009503 | — | D70 | — | — | — | — | 1 | 1 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | — | — | 1 | 1 |
| Thalassemia | D013789 | EFO_1001996 | D56 | — | — | — | — | 1 | 1 |
| Syndrome | D013577 | — | — | — | — | — | — | 1 | 1 |
| Wiskott-aldrich syndrome | D014923 | EFO_0003903 | D82.0 | — | — | — | — | 1 | 1 |
| Diamond-blackfan anemia | D029503 | EFO_0004130 | D61.01 | — | — | — | — | 1 | 1 |
| Shwachman-diamond syndrome | D000081003 | — | D61.02 | — | — | — | — | 1 | 1 |
| Fanconi anemia | D005199 | Orphanet_84 | D61.09 | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Alefacept |
| INN | alefacept |
| Description | Lymphocyte function-associated antigen 3 precursor (Ag3) (Antigen CD58) |
| Classification | Protein |
| Drug class | receptor molecules or membrane ligands, natural, modified or modified: lymphocyte function-associated antigen 3 (LFA) receptors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201571 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00092 |
| UNII ID | ELK3V90G6C (ChemIDplus, GSRS) |
Target
Agency Approved
CD2
CD2
Organism
Homo sapiens
Gene name
CD2
Gene synonyms
SRBC
NCBI Gene ID
Protein name
T-cell surface antigen CD2
Protein synonyms
CD2, CD2 antigen (p50), sheep red blood cell receptor, Erythrocyte receptor, LFA-2, LFA-3 receptor, lymphocyte-function antigen-2, Rosette receptor, T-cell surface antigen T11/Leu-5
Uniprot ID
Mouse ortholog
Cd2 (12481)
T-cell surface antigen CD2 (Q61394)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,220 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,595 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use